Paclitaxel can exert
therapeutic effects by interacting with microtubules.
Stathmin and β-III-
tubulin, which have impact on microtubule activity, are believed to be involved in the
chemotherapy. The purpose of the present study was to evaluate the associations between
stathmin and β-III-
tubulin expression and treatment response and survivals in patients with
non-small cell lung cancer (NSCLC). Two hundred thirty-eight patients who were treated by
platinum-based
chemotherapy were enrolled in this study, among them, 111 patients also received
paclitaxel treatment.
Formalin-fixed and
paraffin-embedded
tumor tissues were collected for
messenger RNA (
mRNA) and
protein detection. We assessed the associations of the two molecules with treatment response and survival outcome. High level of
stathmin exhibited poor response to
chemotherapy (for
mRNA, P = 0.041; for
protein, P = 0.017). Overexpression of
stathmin was associated with shorter overall survival (for
mRNA, P = 0.012; for
protein, P = 0.014) and progression-free survival (for
mRNA, P = 0.039; for
protein, P = 0.022). Of note, this association was only observed in patients who were treated by both
platinum and
paclitaxel. Similar effects were not observed for β-III-
tubulin. The findings demonstrated that
paclitaxel effect may be interfered with
stathmin; overexpression of
stathmin is a predictive marker for a worse prognosis in patients with NSCLC who were treated by both
platinum and
paclitaxel chemotherapy.